Annual CFI
$212.30 M
+$593.60 M+155.68%
31 December 2023
Summary:
Emergent BioSolutions annual cash flow from investing activities is currently $212.30 million, with the most recent change of +$593.60 million (+155.68%) on 31 December 2023. During the last 3 years, it has risen by +$364.20 million (+239.76%). EBS annual CFI is now at all-time high.EBS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$112.00 M
+$116.60 M+2534.78%
30 September 2024
Summary:
Emergent BioSolutions quarterly cash flow from investing activities is currently $112.00 million, with the most recent change of +$116.60 million (+2534.78%) on 30 September 2024. Over the past year, it has increased by +$130.90 million (+692.59%). EBS quarterly CFI is now -56.54% below its all-time high of $257.70 million, reached on 30 June 2023.EBS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$85.20 M
+$130.90 M+286.43%
30 September 2024
Summary:
Emergent BioSolutions TTM cash flow from investing activities is currently $85.20 million, with the most recent change of +$130.90 million (+286.43%) on 30 September 2024. Over the past year, it has dropped by -$93.10 million (-52.22%). EBS TTM CFI is now -60.66% below its all-time high of $216.60 million, reached on 31 March 2024.EBS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +155.7% | +692.6% | -52.2% |
| 3 y3 years | +239.8% | +302.9% | +139.6% |
| 5 y5 years | +123.7% | +832.0% | +109.4% |
EBS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +155.7% | -56.5% | +141.2% | -60.7% | +122.3% |
| 5 y | 5 years | at high | +123.7% | -56.5% | +141.2% | -60.7% | +109.4% |
| alltime | all time | at high | +123.7% | -56.5% | +113.2% | -60.7% | +109.3% |
Emergent BioSolutions Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $112.00 M(-2534.8%) | $85.20 M(-286.4%) |
| June 2024 | - | -$4.60 M(-57.4%) | -$45.70 M(-121.1%) |
| Mar 2024 | - | -$10.80 M(-5.3%) | $216.60 M(+2.0%) |
| Dec 2023 | $212.30 M(-155.7%) | -$11.40 M(-39.7%) | $212.30 M(+19.1%) |
| Sept 2023 | - | -$18.90 M(-107.3%) | $178.30 M(-339.7%) |
| June 2023 | - | $257.70 M(-1806.6%) | -$74.40 M(-79.6%) |
| Mar 2023 | - | -$15.10 M(-66.7%) | -$364.20 M(-4.5%) |
| Dec 2022 | -$381.30 M(+70.1%) | -$45.40 M(-83.3%) | -$381.30 M(-0.1%) |
| Sept 2022 | - | -$271.60 M(+746.1%) | -$381.70 M(+130.9%) |
| June 2022 | - | -$32.10 M(-0.3%) | -$165.30 M(-17.4%) |
| Mar 2022 | - | -$32.20 M(-29.7%) | -$200.20 M(-10.7%) |
| Dec 2021 | -$224.10 M(+47.5%) | -$45.80 M(-17.0%) | -$224.10 M(+4.1%) |
| Sept 2021 | - | -$55.20 M(-17.6%) | -$215.20 M(+4.6%) |
| June 2021 | - | -$67.00 M(+19.4%) | -$205.70 M(+11.9%) |
| Mar 2021 | - | -$56.10 M(+52.0%) | -$183.80 M(+21.0%) |
| Dec 2020 | -$151.90 M(+56.8%) | -$36.90 M(-19.3%) | -$151.90 M(+0.5%) |
| Sept 2020 | - | -$45.70 M(+1.3%) | -$151.10 M(+25.2%) |
| June 2020 | - | -$45.10 M(+86.4%) | -$120.70 M(+21.1%) |
| Mar 2020 | - | -$24.20 M(-33.0%) | -$99.70 M(+2.9%) |
| Dec 2019 | -$96.90 M(-89.2%) | -$36.10 M(+135.9%) | -$96.90 M(-89.3%) |
| Sept 2019 | - | -$15.30 M(-36.5%) | -$909.30 M(-1.2%) |
| June 2019 | - | -$24.10 M(+12.6%) | -$920.10 M(+1.4%) |
| Mar 2019 | - | -$21.40 M(-97.5%) | -$907.00 M(+1.1%) |
| Dec 2018 | -$897.20 M(+259.0%) | -$848.50 M(+3151.0%) | -$897.20 M(+250.2%) |
| Sept 2018 | - | -$26.10 M(+137.3%) | -$256.22 M(+5.5%) |
| June 2018 | - | -$11.00 M(-5.2%) | -$242.90 M(+0.7%) |
| Mar 2018 | - | -$11.60 M(-94.4%) | -$241.20 M(-3.5%) |
| Dec 2017 | -$249.90 M(+228.0%) | -$207.52 M(+1524.3%) | -$249.90 M(+300.9%) |
| Sept 2017 | - | -$12.78 M(+37.4%) | -$62.34 M(-6.3%) |
| June 2017 | - | -$9.30 M(-54.2%) | -$66.56 M(-15.0%) |
| Mar 2017 | - | -$20.30 M(+1.7%) | -$78.29 M(+2.7%) |
| Dec 2016 | -$76.20 M(+67.6%) | -$19.96 M(+17.4%) | -$76.20 M(+11.9%) |
| Sept 2016 | - | -$17.00 M(-19.2%) | -$68.07 M(+4.7%) |
| June 2016 | - | -$21.03 M(+15.5%) | -$65.03 M(+19.1%) |
| Mar 2016 | - | -$18.21 M(+54.0%) | -$54.59 M(+20.1%) |
| Dec 2015 | -$45.46 M | -$11.83 M(-15.2%) | -$45.46 M(-10.7%) |
| Sept 2015 | - | -$13.95 M(+31.6%) | -$50.90 M(+20.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | -$10.60 M(+16.7%) | -$42.17 M(+15.9%) |
| Mar 2015 | - | -$9.08 M(-47.4%) | -$36.38 M(-82.7%) |
| Dec 2014 | -$210.05 M(+209.4%) | -$17.26 M(+230.7%) | -$210.05 M(+3.9%) |
| Sept 2014 | - | -$5.22 M(+8.5%) | -$202.14 M(-16.2%) |
| June 2014 | - | -$4.81 M(-97.4%) | -$241.34 M(-0.7%) |
| Mar 2014 | - | -$182.76 M(+1853.8%) | -$242.97 M(+257.9%) |
| Dec 2013 | -$67.89 M(+69.3%) | -$9.35 M(-78.9%) | -$67.89 M(-5.0%) |
| Sept 2013 | - | -$44.42 M(+589.3%) | -$71.44 M(+92.8%) |
| June 2013 | - | -$6.44 M(-16.1%) | -$37.05 M(-5.5%) |
| Mar 2013 | - | -$7.68 M(-40.5%) | -$39.20 M(-2.3%) |
| Dec 2012 | -$40.11 M(-25.7%) | -$12.90 M(+28.7%) | -$40.11 M(-11.9%) |
| Sept 2012 | - | -$10.02 M(+16.6%) | -$45.55 M(-11.3%) |
| June 2012 | - | -$8.59 M(-0.1%) | -$51.34 M(+3.0%) |
| Mar 2012 | - | -$8.60 M(-53.1%) | -$49.82 M(-7.7%) |
| Dec 2011 | -$53.96 M(+130.1%) | -$18.34 M(+16.0%) | -$53.96 M(+19.8%) |
| Sept 2011 | - | -$15.81 M(+123.5%) | -$45.04 M(+30.0%) |
| June 2011 | - | -$7.07 M(-44.5%) | -$34.64 M(+11.1%) |
| Mar 2011 | - | -$12.74 M(+35.3%) | -$31.17 M(+32.9%) |
| Dec 2010 | -$23.46 M(-29.5%) | -$9.41 M(+74.0%) | -$23.46 M(-28.8%) |
| Sept 2010 | - | -$5.41 M(+50.3%) | -$32.95 M(+0.4%) |
| June 2010 | - | -$3.60 M(-28.4%) | -$32.82 M(-2.2%) |
| Mar 2010 | - | -$5.03 M(-73.4%) | -$33.56 M(+0.8%) |
| Dec 2009 | -$33.29 M(+8.0%) | -$18.91 M(+258.0%) | -$33.29 M(+77.8%) |
| Sept 2009 | - | -$5.28 M(+21.7%) | -$18.73 M(+7.8%) |
| June 2009 | - | -$4.34 M(-8.7%) | -$17.36 M(-30.9%) |
| Mar 2009 | - | -$4.75 M(+9.3%) | -$25.14 M(-18.4%) |
| Dec 2008 | -$30.81 M(-29.9%) | -$4.35 M(+10.9%) | -$30.81 M(+5.4%) |
| Sept 2008 | - | -$3.92 M(-67.6%) | -$29.24 M(-25.4%) |
| June 2008 | - | -$12.11 M(+16.1%) | -$39.17 M(+3.3%) |
| Mar 2008 | - | -$10.43 M(+276.3%) | -$37.91 M(-13.8%) |
| Dec 2007 | -$43.97 M(+6.1%) | -$2.77 M(-80.0%) | -$43.97 M(+6.7%) |
| Sept 2007 | - | -$13.85 M(+27.7%) | -$41.20 M(+50.7%) |
| June 2007 | - | -$10.85 M(-34.2%) | -$27.34 M(+65.8%) |
| Mar 2007 | - | -$16.49 M | -$16.49 M |
| Dec 2006 | -$41.45 M(+484.5%) | - | - |
| Dec 2005 | -$7.09 M(-61.0%) | - | - |
| Dec 2004 | -$18.18 M | - | - |
FAQ
- What is Emergent BioSolutions annual cash flow from investing activities?
- What is the all time high annual CFI for Emergent BioSolutions?
- What is Emergent BioSolutions annual CFI year-on-year change?
- What is Emergent BioSolutions quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly CFI year-on-year change?
- What is Emergent BioSolutions TTM cash flow from investing activities?
- What is the all time high TTM CFI for Emergent BioSolutions?
- What is Emergent BioSolutions TTM CFI year-on-year change?
What is Emergent BioSolutions annual cash flow from investing activities?
The current annual CFI of EBS is $212.30 M
What is the all time high annual CFI for Emergent BioSolutions?
Emergent BioSolutions all-time high annual cash flow from investing activities is $212.30 M
What is Emergent BioSolutions annual CFI year-on-year change?
Over the past year, EBS annual cash flow from investing activities has changed by +$593.60 M (+155.68%)
What is Emergent BioSolutions quarterly cash flow from investing activities?
The current quarterly CFI of EBS is $112.00 M
What is the all time high quarterly CFI for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly cash flow from investing activities is $257.70 M
What is Emergent BioSolutions quarterly CFI year-on-year change?
Over the past year, EBS quarterly cash flow from investing activities has changed by +$130.90 M (+692.59%)
What is Emergent BioSolutions TTM cash flow from investing activities?
The current TTM CFI of EBS is $85.20 M
What is the all time high TTM CFI for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM cash flow from investing activities is $216.60 M
What is Emergent BioSolutions TTM CFI year-on-year change?
Over the past year, EBS TTM cash flow from investing activities has changed by -$93.10 M (-52.22%)